Company news
Angiodynamics, Inc. (NASDAQ:ANGO) news
Every Angiodynamics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
September 28, 2026
AngioDynamics : Press space to expand and collapse this section AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
July 14, 2026
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
July 14, 2026
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
June 30, 2026
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
June 17, 2026
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
May 28, 2026
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
May 13, 2026
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
April 2, 2026
AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
March 31, 2026
AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026
March 19, 2026
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
February 23, 2026
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
February 19, 2026
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
February 5, 2026
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
February 3, 2026
AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability
January 6, 2026
AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026
December 23, 2025
AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 22, 2025
AngioDynamics to Participate in the UBS Global Healthcare Conference
October 27, 2025
AngioDynamics’ NanoKnife® System Named to TIME’s 2025 Best Inventions List
October 13, 2025
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
October 2, 2025
AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025
September 18, 2025
AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference
August 6, 2025
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
July 28, 2025
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology
July 23, 2025
AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth
July 15, 2025
AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025
July 7, 2025
AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism
June 23, 2025
AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F18⁸⁵ System for Treatment of Acute Pulmonary Embolism
June 23, 2025
AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results
April 2, 2025
AngioDynamics to Host Virtual Cardiovascular Investor Event
March 31, 2025
AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event
March 19, 2025
AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference
March 10, 2025
AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia
January 30, 2025
AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI
January 13, 2025
AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results
January 8, 2025
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
January 6, 2025
AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System
January 6, 2025
AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
December 19, 2024
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
December 9, 2024
AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
October 23, 2024
AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
October 21, 2024
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
October 3, 2024
AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
September 19, 2024
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
September 19, 2024
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
September 3, 2024
AngioDynamics to Participate in Upcoming Investor Conferences
July 29, 2024
AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results
July 16, 2024
AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024
July 8, 2024
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
May 21, 2024